Primary living donor liver transplantation for hepatocellular carcinoma versus living donor liver transplantation for postresection recurrent hepatocellular carcinoma: A systematic review

doi:10.3877/cma.j.issn.1674-3903.2017.02.010

Abstract

Abstract:

Objective

To compare the effectiveness and advantage of living donor liver transplantation (LDLT) for postresection recurrent hepatocellular carcinoma (HCC) with primary LDLT for HCC patients.

Methods

Acccording to the including criteria, 4 retrospective studies involving 639 patients were included. RevMan 5.3 software was used for data analysis.

Results

We conducted subgroup analysis based on outcome measures and interventions. Comparing with LDLT for postresection recurrent HCC, primary LDLT had a lower incidence rate of postoperative bleeding (RR=0.36, 95%CI: 0.19-0.68, P<0.05). The incidence rates of vascular complication and biliary complication were similar (RR=0.41, 95%CI: 0.13-1.36, P>0.05; RR=0.80, 95%CI: 0.47-1.36, P>0.05). Likewise, perioperative mortalities did not significantly differ between them (RR=1.24, 95%CI: 0.40-3.88, P>0.05). However, 3-year survival rate was higher among patients who underwent primary living donor liver transplantation (RR=1.28, 95%CI: 1.02-1.61, P<0.05). The 5-year survival rate and 3, 5-year disease-free survival rates showed no statistically significant difference between them (RR=1.10, 95%CI: 0.92-1.33, P>0.05; RR=1.23, 95%CI: 0.91-1.68, P>0.05; RR=1.21, 95%CI: 0.89-1.64, P>0.05).

Conclusion

The long-term effect of LDLT for postresection recurrent HCC is equivalent to primary LDLT, and this therapeutic method is safe and reliable.

Key words: Liver transplantation, Living donor liver transplantation, Hepatocellular carcinoma, Postoperative recurrence, Systematic review

Xufu Wei, Junliang Pu, Zhen Guo, Tong Mou, Tingting Li, Di Zhu, Zhongjun Wu. Primary living donor liver transplantation for hepatocellular carcinoma versus living donor liver transplantation for postresection recurrent hepatocellular carcinoma: A systematic review[J]. Chinese Journal of Transplantation(Electronic Edition), 2017, 11(02): 103-108.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2017.02.010

https://zhyzzz.cma-cmc.com.cn/EN/Y2017/V11/I02/103

Figures/Tables 9

References 20

16	Hu Z,Zhou J,Xu X, et al. Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection[J]. PLoS One, 2012, 7(5): e36587.
17	Chan DL,Alzahrani NA,Morris DL, et al. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2014, 29(1): 31-41.
18	Li HY,Wei YG,Yan LN, et al. Salvage liver transplantation in the treatment of hepatocellular carcinoma: a meta-analysis[J]. World J Gastroenterol, 2012, 18(19): 2415-2422.
1	Majno Pe,Sarasin Fp,Mentha G, et al. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis[J]. Hepatology, 2000, 31(4): 899-906.
2	Slim K,Nini E,Forestier D, et al. Methodological index for nonrandomized studies(minors)：development and validation of a new instrument[J]. ANZ J Surg, 2003, 73(9): 712-716.
3	曾宪涛,庄丽萍,杨宗国, 等. Meta分析系列之七：非随机实验性研究、诊断性试验及动物实验的质量评价工具[J]. 中国循证心血管医学杂志, 2012, 4(6): 496-499.
4	Hwang S,Lee SG,Moon DB, et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma[J]. Liver Transpl, 2007, 13(5): 741-746.
5	Moon JI,Kwon CH,Joh JW, et al. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival[J]. Transplant Proc, 2012, 44(2): 487-493.
6	Kaido T,Mori A,Ogura Y, et al. Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection[J]. Surgery, 2012, 151(1): 55-60.
7	Abe T,Tashiro H,Teraoka Y, et al. Efficacy and feasibility of salvage living donor liver transplantation after initial liver resection in patients with hepatocellular carcinoma[J]. Dig Surg, 2016, 33(1): 8-14.
8	郑树森,俞军,张武. 肝移植在中国的发展现状[J]. 临床肝胆病杂志, 2014, 30(1): 2-4.
9	严律南. 活体肝移植的现状与展望[J]. 中国普外基础与临床杂志, 2007, 14(2): 128-131.
10	郑树森. 活体肝移植的现状与展望[J]. 肝胆外科杂志, 2010, 18(3): 161-163.
11	Hoehn RS,Wilson GC,Wima K, et al. Comparing living donor and deceased donor liver transplant：a matched national analysis from 2007-2012[J]. Liver Transpl, 2014, 20(11): 1347-1355.
12	Quintini C,Hashimoto K,Uso TD, et al. Is there anadvantage of living over deceased donation in liver ransplantation? [J]. Transpl Int, 2013, 26(1): 11-19.
13	Duailibi DF,Ribeiro MA Jr. Biliary complications following deceased and living donor liver transplantation：a review[J]. Transplant Proc, 2010, 42(2): 517-520.
14	Kashyap R,Bozorgzadeh A,Abt P, et al. Stratifying risk of biliary complications in adult living donor liver transplantation by magnetic resonance cholangiography[J]. Transplantation, 2008, 85(11): 1569-1572.
15	Hwang S,Lee SG,Lee YJ, et al. Lessons learned from 1 000 living donor liver transplantations in a single center: how to make living donations safe[J]. Liver Transpl, 2006, 12(6): 920-927.
19	Lee SG. Salvage living-donor liver transplantation to previously hepatectomized hepatocellular carcinoma patients: is it a reasonable strategy？[J]. Hepatobiliary Pancreat Dis Int, 2013, 12(1): 10-11.
20	郑树森. 肝癌肝移植适应证演变与面临问题[J]. 中国实用外科杂志, 2014, 34(8): 681-684.

文献作者(发表时间)	国家	肝癌一期LDLT组			肝癌切除后复发行LDLT组			观察指标
文献作者(发表时间)	国家	例数	男性比例(%)	平均年龄(岁)	例数	男性比例(%)	平均年龄(岁)	观察指标
Hwang (2007年)^[4]	韩国	217	79	51.2	17	70.6	49.3	术后并发症，围术期死亡率，总生存率
Moon (2012年)^[5]	韩国	186	82	52.0	17	94.1	51.0	术后并发症，围术期死亡率，总生存率，无瘤生存率
Kaido (2012年)^[6]	日本	176	69	55.5	19	73.7	52.3	围术期死亡率，总生存率
Abe (2016年)^[7]	日本	60	76	未报道	15	93.3	未报道	术后并发症，总生存率，无瘤生存率

文献作者(发表时间)	国家	肝癌一期LDLT组			肝癌切除后复发行LDLT组			观察指标
文献作者(发表时间)	国家	例数	男性比例(%)	平均年龄(岁)	例数	男性比例(%)	平均年龄(岁)	观察指标
Hwang (2007年)^[4]	韩国	217	79	51.2	17	70.6	49.3	术后并发症，围术期死亡率，总生存率
Moon (2012年)^[5]	韩国	186	82	52.0	17	94.1	51.0	术后并发症，围术期死亡率，总生存率，无瘤生存率
Kaido (2012年)^[6]	日本	176	69	55.5	19	73.7	52.3	围术期死亡率，总生存率
Abe (2016年)^[7]	日本	60	76	未报道	15	93.3	未报道	术后并发症，总生存率，无瘤生存率

[1]	Miao Li, Lianhua Zhu, Peng Han, Bo Jiang, Xiang Fei. Evaluation of relationsip between vascular morphology and risk factors for hepatocellular carcinoma by high-frame-rate contrast-enhanced ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 911-915.
[2]	Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing. Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 930-938.
[3]	Jie Dong, Song Yang, Hao Yang, Xiang Chen, Wanli Zhang. Relationship between hypermethylation of ACACB gene and clinicopathological factors and survival of hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 433-437.
[4]	Wei Huang, Qi Liu, Liuhua Chen, Chaxiang Teng, Zhejian Ou, Hanxiao Liu, Jiancong Chen, Kunsong Zhang. Identification of a pyroptosis-related lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 357-365.
[5]	Kunhe Li, Mengjia Kou, Liting Kuang. Risk factors and prediction model of reintubation after liver transplantation [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 366-371.
[6]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Shanghai Pharmaceutical Profession Association. Expert Consensus on the Use of Mycophenolic Acid in Chinese Liver and Kidney Transplant Recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 257-272.
[7]	Wenqing Lu, Xinyi Chen, Xuefei Ren. Investigation on the quality of life after liver transplantation in children with genetic metabolic diseases [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 287-292.
[8]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[9]	Mei Liao, Hongjun Zhang, Jieyang Jin, Yan Lyu, Jie Ren. Diagnostic value of bedside contrast-enhanced ultrasound for early hepatic artery thrombosis after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 630-634.
[10]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[11]	Binglin Li, Shaocheng Lyu, Fei Pan, Tao Jiang, Hua Fan, Jiantao Kou, Qiang He, Ren Lang. Correlation analysis between pathogenic bacteria of donor liver perfusion fluid and early infection after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 656-660.
[12]	Lei Lyu, Xiao Feng, Kaiming He, Kaining Zeng, Qing Yang, Haijin Lyu, Huimin Yi, Shuhong Yi, Yang Yang, Binsheng Fu. Value of revised King's score in evaluation of live transplantation timing for children with acute liver failure due to Wilson's disease and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 661-668.
[13]	Menglong Wang. Significance of biological characteristics in liver transplantation for HCC [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 490-494.
[14]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[15]	Fengyun Wu, Xin Teng, Lianjuan Liu. Diagnostic value of high-frequency ultrasonography and enhanced magnetic resonance for primary hyperdifferentiated hepatocellular carcinoma of different diameters [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 404-408.

Please choose a citation manager

Content to export